We see a healthier future. It’s within reach.
The Garvan Institute of Medical Research brings together clinicians with world-leading basic and translational researchers. We are patient-focused — our researchers break down barriers between traditional scientific disciplines to find solutions to disease.
Founded in 1963, Garvan’s researchers have made significant advances in genome, epigenome, protein and cell analysis technology. We have revealed causes and treatments for diseases including diabetes, osteoporosis, cancer, immune deficiency and autoimmunity.
Our mission is to harness all the information encoded in our genome to better diagnose, treat, predict and prevent disease.
What makes Garvan special
Garvan’s research has global impact. We lead the field in medical genomics, epigenetics, and cellular genomics; cancer; diseases of immunity and inflammation; and diseases of ageing affecting bone, brain and metabolism.
We are focused on addressing the unmet needs of those living with disease – where better understanding, new treatments and more effective diagnosis can have the biggest impact.
Through cutting-edge technology, facilities, local and international collaborations, Garvan researchers strive, every day, to create a future where everyone lives longer, healthier lives.
Our research scope
We investigate many diseases, from the rarest or un-diagnosable and un-treatable to the most common and widespread. Over more than 50 years, we've made significant breakthroughs in:
- cancer
- diabetes and obesity
- genomics and epigenetics
- neurological diseases like Parkinson's disease, hearing loss and eating disorders
- osteoporosis and bone cancer
- immunological diseases such as asthma, rheumatoid arthritis and Sjögren's syndrome.
Find out more about our laboratories and the diseases we're investigating.
Our research is funded through a crucial combination of peer-reviewed government grants and generous philanthropic investment from the community.
Garvan is affiliated with St Vincent’s Hospital Sydney and UNSW Sydney.
